182 related articles for article (PubMed ID: 32758285)
1. A comprehensive DNA panel next generation sequencing approach supporting diagnostics and therapy prediction in neurooncology.
Lorenz J; Rothhammer-Hampl T; Zoubaa S; Bumes E; Pukrop T; Kölbl O; Corbacioglu S; Schmidt NO; Proescholdt M; Hau P; Riemenschneider MJ
Acta Neuropathol Commun; 2020 Aug; 8(1):124. PubMed ID: 32758285
[TBL] [Abstract][Full Text] [Related]
2. Targeted capture-based NGS is superior to multiplex PCR-based NGS for hereditary BRCA1 and BRCA2 gene analysis in FFPE tumor samples.
Zakrzewski F; Gieldon L; Rump A; Seifert M; Grützmann K; Krüger A; Loos S; Zeugner S; Hackmann K; Porrmann J; Wagner J; Kast K; Wimberger P; Baretton G; Schröck E; Aust D; Klink B
BMC Cancer; 2019 Apr; 19(1):396. PubMed ID: 31029168
[TBL] [Abstract][Full Text] [Related]
3. Validation of the Oncomine
Williams HL; Walsh K; Diamond A; Oniscu A; Deans ZC
Virchows Arch; 2018 Oct; 473(4):489-503. PubMed ID: 30105577
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive Molecular Genetic Analysis in Glioma Patients by Next Generation Sequencing.
Kim T; Lee A; Ahn S; Park JS; Jeun SS; Lee YS
Brain Tumor Res Treat; 2024 Jan; 12(1):23-39. PubMed ID: 38317486
[TBL] [Abstract][Full Text] [Related]
5. Integrating a Large Next-Generation Sequencing Panel into the Clinical Diagnosis of Gliomas Provides a Comprehensive Platform for Classification from FFPE Tissue or Smear Preparations.
Parilla M; Kadri S; Patil SA; Fitzpatrick C; Ritterhouse L; Segal J; Collins J; Pytel P
J Neuropathol Exp Neurol; 2019 Mar; 78(3):257-267. PubMed ID: 30698790
[TBL] [Abstract][Full Text] [Related]
6. Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets.
Sahm F; Schrimpf D; Jones DT; Meyer J; Kratz A; Reuss D; Capper D; Koelsche C; Korshunov A; Wiestler B; Buchhalter I; Milde T; Selt F; Sturm D; Kool M; Hummel M; Bewerunge-Hudler M; Mawrin C; Schüller U; Jungk C; Wick A; Witt O; Platten M; Herold-Mende C; Unterberg A; Pfister SM; Wick W; von Deimling A
Acta Neuropathol; 2016 Jun; 131(6):903-10. PubMed ID: 26671409
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic Detection of Allelic Losses and Imbalances by Next-Generation Sequencing: 1p/19q Co-Deletion Analysis of Gliomas.
Dubbink HJ; Atmodimedjo PN; van Marion R; Krol NMG; Riegman PHJ; Kros JM; van den Bent MJ; Dinjens WNM
J Mol Diagn; 2016 Sep; 18(5):775-786. PubMed ID: 27461031
[TBL] [Abstract][Full Text] [Related]
8. Molecular Diagnostics of Gliomas Using Next Generation Sequencing of a Glioma-Tailored Gene Panel.
Zacher A; Kaulich K; Stepanow S; Wolter M; Köhrer K; Felsberg J; Malzkorn B; Reifenberger G
Brain Pathol; 2017 Mar; 27(2):146-159. PubMed ID: 26919320
[TBL] [Abstract][Full Text] [Related]
9. Next generation sequencing in cancer: opportunities and challenges for precision cancer medicine.
Paolillo C; Londin E; Fortina P
Scand J Clin Lab Invest Suppl; 2016; 245():S84-91. PubMed ID: 27542004
[TBL] [Abstract][Full Text] [Related]
10. Multicenter validation of cancer gene panel-based next-generation sequencing for translational research and molecular diagnostics.
Hirsch B; Endris V; Lassmann S; Weichert W; Pfarr N; Schirmacher P; Kovaleva V; Werner M; Bonzheim I; Fend F; Sperveslage J; Kaulich K; Zacher A; Reifenberger G; Köhrer K; Stepanow S; Lerke S; Mayr T; Aust DE; Baretton G; Weidner S; Jung A; Kirchner T; Hansmann ML; Burbat L; von der Wall E; Dietel M; Hummel M
Virchows Arch; 2018 Apr; 472(4):557-565. PubMed ID: 29374318
[TBL] [Abstract][Full Text] [Related]
11. Assessment of Capture and Amplicon-Based Approaches for the Development of a Targeted Next-Generation Sequencing Pipeline to Personalize Lymphoma Management.
Hung SS; Meissner B; Chavez EA; Ben-Neriah S; Ennishi D; Jones MR; Shulha HP; Chan FC; Boyle M; Kridel R; Gascoyne RD; Mungall AJ; Marra MA; Scott DW; Connors JM; Steidl C
J Mol Diagn; 2018 Mar; 20(2):203-214. PubMed ID: 29429887
[TBL] [Abstract][Full Text] [Related]
12. High-throughput detection of clinically targetable alterations using next-generation sequencing.
Vendrell JA; Grand D; Rouquette I; Costes V; Icher S; Selves J; Larrieux M; Barbe A; Brousset P; Solassol J
Oncotarget; 2017 Jun; 8(25):40345-40358. PubMed ID: 28404952
[TBL] [Abstract][Full Text] [Related]
13. Targeted next-generation sequencing of pediatric neuro-oncology patients improves diagnosis, identifies pathogenic germline mutations, and directs targeted therapy.
Kline CN; Joseph NM; Grenert JP; van Ziffle J; Talevich E; Onodera C; Aboian M; Cha S; Raleigh DR; Braunstein S; Torkildson J; Samuel D; Bloomer M; Campomanes AGA; Banerjee A; Butowski N; Raffel C; Tihan T; Bollen AW; Phillips JJ; Korn WM; Yeh I; Bastian BC; Gupta N; Mueller S; Perry A; Nicolaides T; Solomon DA
Neuro Oncol; 2017 May; 19(5):699-709. PubMed ID: 28453743
[TBL] [Abstract][Full Text] [Related]
14. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
Tan AC; Lai GGY; Tan GS; Poon SY; Doble B; Lim TH; Aung ZW; Takano A; Tan WL; Ang MK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim AST; Lim WT; Toh CK; Tan EH; Lim TKH; Tan DSW
Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042
[TBL] [Abstract][Full Text] [Related]
15. A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.
Dietel M; Jöhrens K; Laffert MV; Hummel M; Bläker H; Pfitzner BM; Lehmann A; Denkert C; Darb-Esfahani S; Lenze D; Heppner FL; Koch A; Sers C; Klauschen F; Anagnostopoulos I
Cancer Gene Ther; 2015 Sep; 22(9):417-30. PubMed ID: 26358176
[TBL] [Abstract][Full Text] [Related]
16. Molecular diagnostics enables detection of actionable targets: the Pediatric Targeted Therapy 2.0 registry.
Ecker J; Selt F; Sturm D; Sill M; Korshunov A; Hirsch S; Capper D; Dikow N; Sutter C; Müller C; Sigaud R; Eggert A; Simon T; Niehues T; von Deimling A; Pajtler KW; van Tilburg CM; Jones DTW; Sahm F; Pfister SM; Witt O; Milde T
Eur J Cancer; 2023 Feb; 180():71-84. PubMed ID: 36542877
[TBL] [Abstract][Full Text] [Related]
17. Development and validation of an ultra-high sensitive next-generation sequencing assay for molecular diagnosis of clinical oncology.
Liang J; She Y; Zhu J; Wei L; Zhang L; Gao L; Wang Y; Xing J; Guo Y; Meng X; Li P
Int J Oncol; 2016 Nov; 49(5):2088-2104. PubMed ID: 27826616
[TBL] [Abstract][Full Text] [Related]
18. Amplicon-Based NGS Panels for Actionable Cancer Target Identification in Follicular Cell-Derived Thyroid Neoplasia.
Madsen MB; Kiss K; Cilius Nielsen F; Bennedbæk FN; Rossing M
Front Endocrinol (Lausanne); 2020; 11():146. PubMed ID: 32265839
[TBL] [Abstract][Full Text] [Related]
19. A tailored molecular profiling programme for children with cancer to identify clinically actionable genetic alterations.
George SL; Izquierdo E; Campbell J; Koutroumanidou E; Proszek P; Jamal S; Hughes D; Yuan L; Marshall LV; Carceller F; Chisholm JC; Vaidya S; Mandeville H; Angelini P; Wasti A; Bexelius T; Thway K; Gatz SA; Clarke M; Al-Lazikani B; Barone G; Anderson J; Tweddle DA; Gonzalez D; Walker BA; Barton J; Depani S; Eze J; Ahmed SW; Moreno L; Pearson A; Shipley J; Jones C; Hargrave D; Jacques TS; Hubank M; Chesler L
Eur J Cancer; 2019 Nov; 121():224-235. PubMed ID: 31543384
[TBL] [Abstract][Full Text] [Related]
20. Targeted next-generation sequencing panel (TruSight Tumor 170) in diffuse glioma: a single institutional experience of 135 cases.
Na K; Kim HS; Shim HS; Chang JH; Kang SG; Kim SH
J Neurooncol; 2019 May; 142(3):445-454. PubMed ID: 30710203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
